Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) EBITDA Margin: 2016-2025

Historic EBITDA Margin for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to 11,045.88%.

  • Rocket Pharmaceuticals' EBITDA Margin fell 369383.00% to 11,045.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 13,245.80%, marking a year-over-year decrease of 129430.00%. This contributed to the annual value of 14,485.95% for FY2024, which is 63747.00% up from last year.
  • Per Rocket Pharmaceuticals' latest filing, its EBITDA Margin stood at 11,045.88% for Q3 2025, which was down 26.57% from 15,042.07% recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' EBITDA Margin peaked at 15,650.11% during Q2 2024, and registered a low of 2,268.48% during Q1 2021.
  • For the 3-year period, Rocket Pharmaceuticals' EBITDA Margin averaged around 13,915.80%, with its median value being 13,950.75% (2023).
  • Per our database at Business Quant, Rocket Pharmaceuticals' EBITDA Margin spiked by 1,224,585bps in 2021 and then slumped by 369,383bps in 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' EBITDA Margin (Quarterly) stood at 9,575.16% in 2021, then surged by 521,756bps to 14,792.72% in 2022, then crashed by 132,910bps to 13,463.62% in 2023, then plummeted by 20,907bps to 13,254.55% in 2024, then tumbled by 369,383bps to 11,045.88% in 2025.
  • Its EBITDA Margin was 11,045.88% in Q3 2025, compared to 15,042.07% in Q2 2025 and 13,641.53% in Q1 2025.